COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 518

Article download: 183

Indian Journal of Pharmacy and Pharmacology

Gabapentin as a Novel Drug

Full Text PDF Share on Facebook Share on Twitter

Author Details : Semira

Volume : 2, Issue : 4, Year : 2015

Article Page : 226-229

Suggest article by email


Background: Gabapentin is an antiepileptic and analgesic drug. There is an urge for reliable scientific evidence to support its ongoing widespread use for treatment of a number of other conditions as well.
Objective: Critical appraisal of the available literature on pharmacological basis of approved and off-label uses of gabapentin to assess the scope for its new roles in therapeutics.
Data Source: A systematic review of literature was made to study history, pharmacology, approved uses and off-label uses of gabapentin.
Conclusion: Gabapentin use has extended into the management of a variety of disorders besides epilepsy, neuropathic pain and restless leg syndrome. A large number of clinical trials are conducted to establish its role in a wide spectrum of clinical situations. While tremendous scientific speculations are surrounding the drug; there is a need to know more about this novel drug including its mechanism of action and adverse effect profile.

Key words:
Gabapentin, off-label, anticonvulsant

How to cite : Semira, Gabapentin as a Novel Drug. Indian J Pharm Pharmacol 2015;2(4):226-229

Copyright © 2015 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (